Figures computed from official regulatory filings — .
Company financials
ProfessionalRevenue, margins, P/E and more come with the Professional plan.
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Pentixapharm Holding AG only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for functional adrenal tumors, which is in Phase II study. It also develops anti-GlycoTarget antibodies to treat solid tumors. In addition, the company's PentixaFor is being developed as a diagnostic tool for primary hypertension, a cause of hypertension, which is in Phase III trial. Further, its pipeline products for oncology indications include PT-00X, GT-00X, GT-001, GT-002, GT-005, and GT-008. Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.
Market information source · Sep 9, 2026
Open-market timeline · full history
4 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Details | |
|---|---|---|---|---|
| Eckert Wagniskapital und Frühphasenfinanzierung GmbH | Other | $8.5M | BAFIN |
| Eckert Wagniskapital und Frühphasenfinanzierung GmbH | Buy | $115.1K | BAFIN |
| Eckert Wagniskapital und Frühphasenfinanzierung GmbH | Buy | $119.1K | BAFIN |
| Eckert Wagniskapital und Frühphasenfinanzierung GmbH | Buy | $318.6K | BAFIN |
| Eckert Wagniskapital und Frühphasenfinanzierung GmbH | Buy | $90.9K | BAFIN |